These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 10444196

  • 21. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR, Martin MB.
    N Engl J Med; 1998 Dec 03; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract] [Full Text] [Related]

  • 22. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
    Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R.
    Blood; 2006 May 01; 107(9):3738-44. PubMed ID: 16352815
    [Abstract] [Full Text] [Related]

  • 23. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
    Marshall R, Tricta F, Galanello R, Leoni G, Kirkland D, Minto S, Spino M.
    Mutagenesis; 2003 Sep 01; 18(5):457-63. PubMed ID: 12960415
    [Abstract] [Full Text] [Related]

  • 24. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K, Pyar K, Wonke B.
    Med J Malaysia; 2000 Dec 01; 55(4):493-7. PubMed ID: 11221163
    [Abstract] [Full Text] [Related]

  • 25. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
    Pepe A, Meloni A, Pistoia L, Cuccia L, Gamberini MR, Lisi R, D'Ascola DG, Rosso R, Allò M, Spasiano A, Restaino G, Righi R, Mangione M, Positano V, Ricchi P.
    Br J Haematol; 2018 Dec 01; 183(5):783-795. PubMed ID: 30334574
    [Abstract] [Full Text] [Related]

  • 26. Deferiprone: greater efficacy at depleting myocardial than hepatic iron?
    Richardson DR.
    Lancet; 2002 Aug 17; 360(9332):501-2. PubMed ID: 12241649
    [No Abstract] [Full Text] [Related]

  • 27. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.
    Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V.
    J Cardiovasc Magn Reson; 2009 Jun 28; 11(1):20. PubMed ID: 19558722
    [Abstract] [Full Text] [Related]

  • 28. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 28; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 29. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec 28; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

  • 30. Long-term trials of deferiprone in Cooley's anemia.
    Olivieri NF, Brittenham GM.
    Ann N Y Acad Sci; 1998 Jun 30; 850():217-22. PubMed ID: 9668542
    [Abstract] [Full Text] [Related]

  • 31. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 32. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV.
    Br J Haematol; 1992 Oct 10; 82(2):431-6. PubMed ID: 1419825
    [Abstract] [Full Text] [Related]

  • 33. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N, Ali S, Butt MA.
    J Ayub Med Coll Abbottabad; 2014 Oct 10; 26(3):297-300. PubMed ID: 25671931
    [Abstract] [Full Text] [Related]

  • 34. Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience.
    Pati HP, Choudhry VP.
    Eur J Haematol; 1999 Oct 10; 63(4):267-8. PubMed ID: 10530416
    [No Abstract] [Full Text] [Related]

  • 35. [Epidemiological and economic aspects of chelating therapy in the therapeutic center of thalassemia in Morocco].
    Agouzal M, Quyou A, Benchekroune K, Khattab M.
    Rev Med Brux; 2010 Oct 10; 31(2):79-87. PubMed ID: 20677662
    [Abstract] [Full Text] [Related]

  • 36. Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine.
    Mangiagli A, De Sanctis V, Campisi S, Di Silvestro G, Urso L.
    J Pediatr Endocrinol Metab; 2000 Jun 10; 13(6):677-80. PubMed ID: 10905396
    [Abstract] [Full Text] [Related]

  • 37. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
    Piga A, Gaglioti C, Fogliacco E, Tricta F.
    Haematologica; 2003 May 10; 88(5):489-96. PubMed ID: 12745268
    [Abstract] [Full Text] [Related]

  • 38. Oral iron chelation therapy for thalassaemia: an uncertain scene.
    Pippard MJ, Weatherall DJ.
    Br J Haematol; 2000 Oct 10; 111(1):2-5. PubMed ID: 11091177
    [No Abstract] [Full Text] [Related]

  • 39. Thalassaemia major: the murky story of deferiprone.
    Savulescu J.
    BMJ; 2004 Feb 14; 328(7436):358-9. PubMed ID: 14962851
    [No Abstract] [Full Text] [Related]

  • 40. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
    Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ.
    Lancet; 2002 Aug 17; 360(9332):516-20. PubMed ID: 12241655
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.